Caption Management LLC Reduces Stake in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Caption Management LLC trimmed its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 59.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 53,844 shares of the company's stock after selling 78,556 shares during the period. Caption Management LLC owned about 0.12% of Pacira BioSciences worth $1,014,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the stock. BOKF NA bought a new position in Pacira BioSciences in the fourth quarter worth about $562,000. Bridgeway Capital Management LLC raised its holdings in shares of Pacira BioSciences by 3.2% during the fourth quarter. Bridgeway Capital Management LLC now owns 358,785 shares of the company's stock valued at $6,760,000 after buying an additional 11,149 shares during the last quarter. Brevan Howard Capital Management LP acquired a new position in shares of Pacira BioSciences during the fourth quarter valued at approximately $637,000. Balyasny Asset Management L.P. acquired a new position in Pacira BioSciences in the fourth quarter worth approximately $8,180,000. Finally, Ameriprise Financial Inc. grew its position in Pacira BioSciences by 150.1% in the fourth quarter. Ameriprise Financial Inc. now owns 324,261 shares of the company's stock worth $6,109,000 after buying an additional 194,597 shares during the last quarter. 99.73% of the stock is owned by hedge funds and other institutional investors.

Pacira BioSciences Price Performance

Shares of NASDAQ:PCRX traded up $0.37 during midday trading on Monday, hitting $25.49. The stock had a trading volume of 489,682 shares, compared to its average volume of 890,819. The company's 50-day moving average price is $24.73 and its 200-day moving average price is $22.17. The company has a market capitalization of $1.18 billion, a P/E ratio of -12.57 and a beta of 0.56. Pacira BioSciences, Inc. has a fifty-two week low of $11.16 and a fifty-two week high of $31.67. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Needham & Company LLC decreased their price target on shares of Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating on the stock in a research report on Friday. HC Wainwright lifted their price target on shares of Pacira BioSciences from $48.00 to $65.00 and gave the stock a "buy" rating in a research report on Tuesday, April 8th. Royal Bank of Canada reiterated a "sector perform" rating and set a $18.00 price objective on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Truist Financial raised shares of Pacira BioSciences from a "sell" rating to a "hold" rating and boosted their target price for the stock from $8.00 to $25.00 in a research report on Thursday, January 30th. Finally, Barclays boosted their target price on shares of Pacira BioSciences from $17.00 to $24.00 and gave the stock an "overweight" rating in a research report on Friday, February 28th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $26.44.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.